Abstract
Currently it is well known that all biological drugs, including those with a fully human structure, are capable of inducing a host immune response known as immunogenicity [1]. The presence of ADAs can condition the drug´s level and action, thus modifying the therapeutic effect and even the safety profile by its mechanism of action - neutralizing or non-neutralizing - and / or an increase in its clearance. Immunogenicity is a dynamic factor to be taken into account in biological therapy, especially in long-term treatments, and as a relevant aspect in the assessment of secondary response loss [2]. With the above, not only the knowledge but also the management of the immunogenicity of the different biological treatments, represent a useful instrument for optimization of the strategies of use for each drug, and in the design of predictive models of response, which finally permits a significant improvement in the efficacy and safety profile, aiming to a personalization of the therapies, especially in patients with autoimmune diseases, genetic disorders and cancer [3]. This review summarizes the events of immunogenicity that produce the biological drug, the factor that influence to immunogenicity and the assessment of immunogenicity.
Keywords: Immunogenicity, biosensor, peptide, biological drugs, anti-drugs antibodies, ADAs.
Current Protein & Peptide Science
Title:Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview
Volume: 19 Issue: 10
Author(s): L. Fernandez, R.H. Bustos*, C. Zapata, J. Garcia, E. Jauregui and G.M. Ashraf
Affiliation:
- Evidence-Based Therapeutic Group, Clinical Pharmacology, Universidad de La Sabana, Chia,Colombia
Keywords: Immunogenicity, biosensor, peptide, biological drugs, anti-drugs antibodies, ADAs.
Abstract: Currently it is well known that all biological drugs, including those with a fully human structure, are capable of inducing a host immune response known as immunogenicity [1]. The presence of ADAs can condition the drug´s level and action, thus modifying the therapeutic effect and even the safety profile by its mechanism of action - neutralizing or non-neutralizing - and / or an increase in its clearance. Immunogenicity is a dynamic factor to be taken into account in biological therapy, especially in long-term treatments, and as a relevant aspect in the assessment of secondary response loss [2]. With the above, not only the knowledge but also the management of the immunogenicity of the different biological treatments, represent a useful instrument for optimization of the strategies of use for each drug, and in the design of predictive models of response, which finally permits a significant improvement in the efficacy and safety profile, aiming to a personalization of the therapies, especially in patients with autoimmune diseases, genetic disorders and cancer [3]. This review summarizes the events of immunogenicity that produce the biological drug, the factor that influence to immunogenicity and the assessment of immunogenicity.
Export Options
About this article
Cite this article as:
Fernandez L., Bustos R.H.*, Zapata C., Garcia J., Jauregui E. and Ashraf G.M., Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview, Current Protein & Peptide Science 2018; 19 (10) . https://dx.doi.org/10.2174/1389203718666170828123449
DOI https://dx.doi.org/10.2174/1389203718666170828123449 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Artificial Intelligence for Protein Research
Protein research, essential for understanding biological processes and creating therapeutics, faces challenges due to the intricate nature of protein structures and functions. Traditional methods are limited in exploring the vast protein sequence space efficiently. Artificial intelligence (AI) and machine learning (ML) offer promising solutions by improving predictions and speeding up ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression
Current Pharmaceutical Design An Unusual Presentation of a Rare Scleroderma Mimic: What is Behind the Scenes?
Current Rheumatology Reviews Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry Autoimmune Disorders during Pregnancy: Effects of Biomarkers on Maternal Serum Screening and Course of Disease
Current Women`s Health Reviews NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design The Study of HLA Class II and Autoimmune Diabetes
Current Molecular Medicine CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Mesenchymal Stem Cell as a Potential Therapeutic for Inflammatory Bowel Disease- Myth or Reality?
Current Stem Cell Research & Therapy Analogs of the Sea Anemone Potassium Channel Blocker ShK for the Treatment of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Food Ingredients and Lipid Mediators
Current Nutrition & Food Science Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia
Current Pharmaceutical Design One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Therapy for Immunologic Tolerance: Using Bone Marrow-Derived Cells to Treat Autoimmunity and Hemophilia
Current Stem Cell Research & Therapy Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Natural Killer T Cells and Autoimmune Disease
Current Molecular Medicine Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry